Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.48 |
| ▸ | TUBB | P07437 | 2/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899143 | 1.00 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6941813 | 0.82 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6110179 | 0.80 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6523898 | 0.79 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9059778 | 0.77 | STAT3 (0.47) | MEN1KMT2AESR1GAAESR2 | |
| SCHEMBL7064499 | 0.77 | FTO (0.46) | MEN1KMT2AESR1GAAESR2 | |
| SCHEMBL6110743 | 0.76 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1195874 | 0.76 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8895421 | 0.75 | WDR5 (0.50) | WDR5MEN1KMT2AGAALDHA | |
| Carboxynaphthol SCHEMBL2454960 | 0.75 | LDHA (0.65) | WDR5MEN1KMT2AGAALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017992-B2 | Compounds for modulating mitochondrial function | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-09-14 | — | — | US | disclosed |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-08-15 | — | — | US | disclosed |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-01-26 | — | — | US | disclosed |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-07-12 | — | — | US | disclosed |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2022-02-03 | — | — | US | disclosed |
| US-20220017467-A1 | COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-01-20 | — | — | US | disclosed |
| US-11161814-B2 | Compounds for modulating mitochondrial function | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092861-A1 | QUINOLINONE DERIVATIVES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005090288-A1 | PHENYLAMINOETHANOL DERIVATES AS BETA2 RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | TUBB4A 373/4885TUBB 198/4885TUBA3C 468/4885 |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | TUBB4A 678/4885TUBB 382/4885TUBA3C 944/4885 |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | TUBB4A 678/4885TUBB 382/4885TUBA3C 944/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | TUBB4A 247/4885TUBB 116/4885TUBA3C 122/4885 |
| US-20220017467-A1 | COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION | CYC1, UQCRC1, NLN | TUBB4A 1365/4885TUBB 1036/4885TUBA3C 715/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | TUBB4A 678/4885TUBB 382/4885TUBA3C 944/4885 |
| US-11161814-B2 | Compounds for modulating mitochondrial function | CYC1, UQCRC1, NLN | TUBB4A 1365/4885TUBB 1036/4885TUBA3C 715/4885 |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | TUBB4A 678/4885TUBB 382/4885TUBA3C 944/4885 |
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | TUBB4A 676/4885TUBB 652/4885TUBA3C 721/4885 |
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | TUBB4A 711/4885TUBB 698/4885TUBA3C 802/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | TUBB4A 737/4885TUBB 692/4885TUBA3C 725/4885 |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | TUBB4A 678/4885TUBB 382/4885TUBA3C 944/4885 |
| US-12017992-B2 | Compounds for modulating mitochondrial function | CYC1, UQCRC1, NLN | TUBB4A 1365/4885TUBB 1036/4885TUBA3C 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.